Merial Limited

Boehringer Ingelheim Animal Health USA Inc.

Zahia Hannas-Djebbara

Jules Maarten Minke

Herve Poulet

Frederic Raymond David

Jean-Christophe Francis Audonnet

Teshome Mebatsion

Frédéric Reynard

Justin Widener

Yu-Wei Chiang

Frederic David

The present disclosure encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs are formed by the CPV VP2 protein. Further, the disclosure broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.

Canine parvovirus (CPV) virus-like particle (VLP) vaccines and uses thereof

The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.

The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.

FMDV recombinant vaccines and uses thereof

Growing community of inventors

Francheville, France

Zahia Hannas-Djebbara